We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Biotech Acquisition Company (“Biotech Acquisition” or the “Company”) (NASDAQ: BIOT) with Blade Therapeutics, Inc. Under the terms of the merger, Biotech Acquisition shareholders will retain ownership of only 39.6% of the combined company.
The Biotech Acquisition merger investigation concerns whether the Board of Biotech Acquisition has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.